Dapagliflozin alleviates myocardial ischemia/reperfusion injury by reducing ferroptosis via MAPK signaling inhibition

Reperfusion is essential for ischemic myocardium but paradoxically leads to myocardial damage that worsens cardiac functions. Ferroptosis often occurs in cardiomyocytes during ischemia/reperfusion (I/R). The SGLT2 inhibitor dapagliflozin (DAPA) exerts cardioprotective effects independent of hypoglyc...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	Weixiang Chen, Yue Zhang, Zuoxiang Wang, Mingyue Tan, Jia Lin, Xiaodong Qian, Hongxia Li, Tingbo Jiang
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	Frontiers Media S.A. 2023-02-01
Цуврал:	Frontiers in Pharmacology
Нөхцлүүд:	myocardial ischemia/reperfusion dapagliflozin ferroptosis MAPK pathway treatment
Онлайн хандалт:	https://www.frontiersin.org/articles/10.3389/fphar.2023.1078205/full
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!